Company Overview
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.
Recent News
SCYNEXIS Announces $40.0 Million Private Placement
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
Stock Overview
Symbol
SCYX
Exchange
Nasdaq
Market Cap
41.09m
Last Price
$0.92
52-Week Range
$0.56 - $1.31
04/07/2026 02:37 PM EDT